Stock News Staff

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) Q3 Earnings Beat Estimates

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) shares fell 9.09% despite the company posting better than expected third quarter financial results. The clinical-stage immunotherapy company reported a net loss of (-$13.4) million or (-$0.52) cents a share. Analyst were expecting a net loss of (-$0.63) cents a share.

Immune Design Corp (NASDAQ:IMDZ)

Q3 Financial Results

Investor confidence in Immune design has taken a hit in recent weeks, seen by the stock trading near all-time lows. The stock is down by more than 50% for the year.

Immune Design Corp (NASDAQ:IMDZ) posted revenues of $0.5 million for the three months ended September 30, 2017. The revenue is primarily attributable to collaboration revenues associated with the Sanofi G103 HSV vaccine product collaboration.

However, it was a decline from revenues of $8.2 million reported last year. Revenue for the corresponding period last year included $7 million in license revenue and $0.4 million in product sales associated with the Sanofi collaboration.

Revenue for the first six months of the year totaled $6.7 million down from $11.2 million for the corresponding period last year. Research and Development expenses in the third quarter totaled $10.2 million compared to $11.2 million for the corresponding period last year. The decrease was primarily attributed to a decline in licensing royalties and fees to other third parties.

Immune Design Corp (NASDAQ:IMDZ) exited the third quarter with cash and cash equivalent of $67.5 million compared to $110.4 million as of December 31, 2016.

Pipeline Development

During the quarter, Immune Design Corp (NASDAQ:IMDZ) achieved an important milestone in the development of its drug pipeline. The FDA approved the Phase 3 trial, design, and approval criteria for the company’s candidate drug for the treatment of synovial sarcoma, CMB305.

“In addition, at ESMO we presented interim analysis data from our ongoing randomized Phase 2 study of CMB305 and atezolizumab showing that patients receiving the combination therapy experienced greater clinical benefit and immune response than those receiving atezolizumab alone,” said CEO, Carlos Paya.

Immune Design Corp (NASDAQ:IMDZ) completed an underwritten follow-on public offering in Q3 that resulted in the sale of 22.4 million shares of common stock. Estimated net proceeds from the offering is $86.6 million. The company plans to use net proceeds from the offering to fund ongoing clinical programs and for working capital.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMDZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

OHR Pharmaceutical Inc (NASDAQ:OHRP)

VIVUS, Inc. (NASDAQ:VVUS) New Lows

VIVUS, Inc. (NASDAQ:VVUS)

Campbell, CA-based VIVUS, Inc. (NASDAQ:VVUS) has established new lows for three days in a row on the back of higher than average volume. In August, the street expected VIVUS, Inc. (NASDAQ:VVUS) to report a Q2 2017 loss of (-$0.13) and that was exactly what occurred. But revenues tumbled almost 19%, to $11.2 million.

VIVUS, Inc. (NASDAQ:VVUS)

In mid-August, VVUS stock broke below the psychologically important $1 per share level and touched $0.86 on September 6. Shares then proceeded to trade higher near the $1 level before tumbling for 13 of the next 15 trading days. Today the shares touched an all-time low of $0.61.

VIVUS Business

VIVUS, Inc. (NASDAQ:VVUS) is a biopharmaceutical company. It develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. Qsymia has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases.

VVUS Stock Performance

Unlike many biotechnology companies, VIVUS, Inc. (NASDAQ:VVUS) has not diluted shareholder equity through additional public share offerings. However its revenues have been inconsistent. In 2013, the company reported sales of $114.2 million followed by annual sales of $95.4 million, and $124.3 million for 2016.

Earnings have been more of a bright spot for the company. From 2012 until 2015, VIVUS, Inc. (NASDAQ:VVUS) reported losses, but for 2016 the company reported a per share profit of $0.22.

VVUS stock has a consensus one-year target price of $2.15. For the year, and prior to today’s price action, the stock has lost almost 35%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VVUS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Leading Brands, Inc (USA) (NASDAQ:LBIX)

Buyers Jump into Leading Brands, Inc (USA) (NASDAQ:LBIX)

Leading Brands, Inc (USA) (NASDAQ:LBIX)

Shares of Leading Brands, Inc (USA) (NASDAQ:LBIX) are up over 50% and reversing the stock’s ten day decline following the company’s earnings announcement for Q2 2017. Observers believe the market is viewing the previous sell-off as overdone. Investors are buying in abnormally large quantities and the stock’s volume is on pace to register a number 20 times the listed daily average.

Leading Brands, Inc (USA) (NASDAQ:LBIX)

Leading Brands, Inc (USA) (NASDAQ:LBIX), headquartered in Vancouver, BC, Canada, and its subsidiaries develop, market, and distribute their own line of branded beverage products. These include TrueBlue, PureBlue, and LiveHappy Water.

Leading Brands Q2 Earnings

On October 16, 2017 Leading Brands, Inc (USA) (NASDAQ:LBIX) announced a $710,000 (-$0.25 per share) net loss from continuing operations versus a net loss of $949,000 (or $0.33 per share) in Q2 2016. Gross revenue for continuing operations for Q2 2017 was $510,000, versus $568,000 in the comparable period of last year. Gross profit margin for the quarter was 0.7%, up from (9.1%) in the same quarter last year.

LBIX Stock Reaction

On October 10, 2017, investors began accumulating shares, reportedly in anticipation of the earnings announcement. Shares boomed from $0.84 to $3.75 on October 13. The day of the announcement, shares reached $3.20 but closed at $2.82.

The failure to sustain the share increase led to a continuous decline. By October 31, LBIX stock hit a daily low of $1.30 – a 65% drop from its October 13 high. But today, investors jumped in and sent LBIX shares back up. They opened at $1.49 and have hit an inter-day high of $2.52. LBIX stock is trading around $2.25 at the time of this writing (11:52 AM EST).

Leading Brands Sales and Earnings History

In 2013, the company posted a per share profit of $0.15 and followed it up the next year with a figure of $0.31. Unfortunately, the next three years have seen losses. For 2015 the per share loss was (-$1.02), then a loss of (-$1.06) for 2016, and a loss of (-$0.86) for FY2017.

Sales have suffered as well. In 2013 sales were reported at $13.4 million and 2014 saw sales of $11.9 million. But in 2015 sales were just $400,000, then the next year just $600,000, and $900,000 for FY2017.

The one-year consensus price target amongst analysts is $4.40.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $LBIX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) Drops After Q3 Net Loss

Ritter Pharmaceuticals Inc. (NASDAQ:RTTR)

Shares of Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) fell 3.4% after the pharmaceutical company reported a (-$2) million net loss. Basic and diluted net loss for the three months ended September 30, 2017, came in at (-$0.14) a share, compared to net loss of (-$0.41) reported last year.

Ritter Pharmaceuticals Inc. (NASDAQ:RTTR)

RTTR Stock Performance

Despite a 42% year-over-year decrease in net loss, investors still pushed the stock lower in the market. Ritter Pharmaceuticals has underperformed the overall industry for the better part of the year. The stock is down by more than 80% for the year.

In defense of the company’s performance, Chief Executive Officer, Michael D. Step said they are committed and focused on the development of RP-G28, for the treatment of lactose intolerance. Plans are already underway to commence Phase 3 trials after a productive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA).

RP-G28 Trials

During the quarter, Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) raised $23 million in an underwritten public offering. Net proceeds from the offering are to be used to finance the proposed Phase 3 trial in the first half of next year. The therapy has the potential to become the first FDA approved treatment for Lactose intolerance.

“With Phase 3 guidance from the FDA from our End of Phase 2 Meeting and our recent successful capital raise behind us, we have a clear regulatory pathway and we have sufficient funding to execute the first pivotal Phase 3 clinical trial of RP-G28 through data readout,” said Andrew J. Ritter President Ritter Pharmaceutical.

Ritter Pharmaceuticals Operating Costs

Ritter Pharmaceuticals Inc. (NASDAQ:RTTR)’s research and development expenses in the quarter totaled $0.9 million primarily attributable to Phase 2b/3 extension study fees of RP-G28 on Phase 3 program planning expenses. However, it was a decline from $2.3 million spent last year.

Total operating expenses in the quarter stood at $2 million compared to $3.5 million reported last year. The decrease was primarily as a result of a decrease in research and development expenses. Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) exited the quarter with cash and cash equivalent of $3.6 million. The cash balance also received a boost of $21 million from a public offering held last month.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RTTR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Drops After Pricing Offering

Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Pluristem Therapeutics Inc. (NASDAQ:PSTI) shares fell 14.7% after announcing the pricing of a previously announced public offering of 9 million shares on the Tel-Aviv Stock Exchange. The developer of placenta-based cell therapy products has priced the offering at $1.67 a share and expects gross proceeds of $15.1 million.

Pluristem Therapeutics Inc. (NASDAQ:PSTI)

PSTI Investors Reaction

The accepted orders in the aggregate amount of $15.1 million after the offering became over-subscribed. The minimum share price consequently increased from $1.61 to $1.67 a share. The offering should close on or about December 31, 2017.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) plans to use net proceeds from the offering for research and product development. Part of the funds will also to be used to finance clinical trial activities, working capital, and for other general corporate purposes.

Investors reacted to the public offering pricing by pushing the stock lower. A point of concern is that the public offering was priced at a discount and that it could lead to further dilution of the stock. However, the stock continues to trade in an uptrend. The stock is up by more than 10% for the year.

PLX-R18 Development

The pricing of the public offering follows the Israel’s Ministry of Health approval of the company’s Phase 1 study of drug candidate PLX-R18. Pluristem Therapeutics Inc. (NASDAQ:PSTI) is investigating the drug candidate for the treatment of insufficient hematopoietic recovery following hematopoietic cell transplantation HCT. The U.S. Food and Drug Administration (FDA) has also approved the trial. In the United States, Pluristem is to recruit up to 30 patients for the trial.

“We’re very pleased with the Israeli Ministry of Health’s vote of confidence in our innovative therapies and efforts to provide treatments for a range of hematopoietic conditions, including insufficient recovery from hematopoietic stem cell transplants,” stated Zami Aberman, Pluristem Co-CEO, and Chairman

In addition, PLX-R18 is in late-stage development as a treatment for acute radiation syndrome (ARS). The cell therapy is designed to treat bone marrow that is unable to produce enough blood cells due to ARS. Pluristem Therapeutics Inc. (NASDAQ:PSTI) holds several patents that cover PLX-r18 for the treatment of impaired hematopoietic systems in case of a bone marrow transplant.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PSTI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Supercom Ltd (NASDAQ:SPCB)

New Highs for Supercom Ltd (NASDAQ:SPCB)

Supercom Ltd (NASDAQ:SPCB)

Buoyed by a Q3 profit of $614,000, shares of Israel-based Supercom Ltd (NASDAQ:SPCB) are up almost 50% in morning trading and hovering around the $4 handle. On a per-share basis, the company said it had net income of $0.04 cents. Earnings, adjusted for one-time gains and costs, were $0.11 cents per share. The traditional and digital identity solutions provider posted revenue of $9.6 million for the period.

Supercom Ltd (NASDAQ:SPCB)

Supercom Ltd (NASDAQ:SPCB) develops and commercializes security software that cover markets including personal identity, machine-to-machine, cyber security device, payment, and connectivity products. Their clients include governments, as well as private and public organizations worldwide. Supercom offers MAGNA, a common platform for ID registries, e-passports, biometric visas, automated fingerprint identification systems, digitized driver’s licenses, and electronic voter registration and election management. It also offers its proprietary PureRF suite – a service based on radio-frequency identification (RFID) tag technology that was designed to identify, locate, track, monitor, count, and protect people and objects.

SPCB Stock

Shareholders will welcome the dramatic increase in revenues. Reported sales have been declining from their 2014 high of $29.7 million and were just $20 million for 2016. Similarly, earnings have also been declining. In 2012, earnings per share were posted at $0.75. That number has decreased each year and for 2016 the company posted a per share loss of (-$0.93)

That decline in sales and earnings led to SPCB shares losing almost 20% year-to-date. Today’s price action, should it continue to stay around $4, will establish a new 52-week high, besting the old $3.98 previous high established at the beginning of the year. The one-year consensus price target for SPCB stock is $4.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SPCB and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

pSivida Corp. (NASDAQ:PSDV) Turns to Strategic Collaboration

pSivida Corp. (NASDAQ:PSDV)

pSivida Corp. (NASDAQ:PSDV) was unchanged in Friday’s trading session, days after announcing a strategic collaboration with Nicox S.A. The collaboration seeks to enhance the development of a sustained-release drug that can lower intraocular pressure in patients with glaucoma or Ocular Hypertension.

pSivida Corp. (NASDAQ:PSDV)

PSDV Stock Performance

pSivida Corp. (NASDAQ:PSDV) shares are currently trading near all-time lows, the stock having been under immense selling pressure since June. Over the past four months, the stock has shed more than 50% in market value as it continues to trade in a downtrend. The company has since turned to strategic collaboration as it seeks to reinvigorate its prospects.

Nicox-pSivida Collaboration

Pursuant to the agreement, the two companies are to collaborate in the selection of NO-donating products from Nicox’s research portfolio, which are to be combined with pSivida’s sustained release drug technology.

“Combining this novel approach to IOP lowering with our bio erodible, a sustained delivery device could offer a unique therapy alternative or adjunct to existing therapies to lower IOP in order to help prevent the development and progression of glaucoma,” said CEO, Nancy Lurker.

pSivida Corp. (NASDAQ:PSDV) has the responsibility of taking care of initial development activities of ocular insert formulations, for which it will receive undisclosed payments from Nicox. Under the terms of the agreement, the two companies may proceed with further development including non-clinical studies needed to generate pre-clinical data.

Nicox is to cater for any expenses that arise from incremental development activities for each product selected to progress into development. The two will negotiate a license agreement for any product that comes out of the collaboration.

Glaucoma Partnership

In addition, pSivida Corp. (NASDAQ:PSDV) has signed an agreement with a major pharmaceutical company for the development of two glaucoma drugs using its proprietary release technology. Under the terms of the agreement, the company is to receive, upfront payments of $750,000 for initial development. Additional payment totaling $200,000 could come into play depending on certain milestones.

“A key focus for pSivida during 2017 is to expand the number of development collaboration agreements with other drug manufacturers and this is the second such agreement during 2017. This agreement extends the strong working relationship between the two organizations,” Lurker in a statement.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PSDV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

MYOS RENS Technology Inc (NASDAQ:MYOS) Muscles Higher

MYOS RENS Technology Inc (NASDAQ:MYOS)

MYOS RENS Technology Inc (NASDAQ:MYOS) stock is up almost 20% with two hours remaining in the trading day. Shares benefitted from the announcement of a partnership with the owner of Fortetropin® in support of the NFL Alumni NY/NJ Chapter’s Optimal Bowl and Wellness Challenge.

MYOS RENS Technology Inc (NASDAQ:MYOS)

MYOS – NFL Alumni Partnership

The 90-day Wellness challenge will feature former NFL players and military veterans working together with world class medical specialists in a variety of activities designed to improve their individual health. Throughout the wellness challenge, the public will be able to follow challenge participants’ journeys to wellness through reality-based web TV documentary series and mass media initiatives that will include preventive health information and educate the public about wellness. This educational competition culminates with the showdown of health and wellness, the Optimal Bowl.

Joseph Mannello, Chief Executive Officer of MYOS RENS Technology Inc (NASDAQ:MYOS) stated “We are happy to be supporting the NFL Alumni in the Optimal Bowl and Wellness Challenge, to raise awareness about the importance of muscle health. It’s a proven fact that we start losing lean muscle with each decade of life, beginning at 30 years of age. Our partnership with the NFL Alumni fits perfectly within our mission of promoting the benefits of Fortetropin® in a regular exercise regimen, regardless of age or physical condition,”

MYOS Stock

MYOS RENS Technology Inc (NASDAQ:MYOS) is up over 25% year-to-date and up over 11% in just the last week. However, the stock is relatively flat over the past year as MYOS shares had spiked early in 2017 and remained above $3.50 for much of January and February. Since then, shares have been sliding.

Sales have been a shadow of what they used to be. In 2013 and 2014 sales were posted at $3.3 million each year. However the company reported sales of $200,000 for 2015 and $300,000 for 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MYOS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Evoke Pharma Inc. (NASDAQ:EVOK) To Submit NDA Application

Evoke Pharma Inc. (NASDAQ:EVOK)

Evoke Pharma Inc. (NASDAQ:EVOK) traded lower after announcing positive top-line results from a comparative exposure pharmacokinetic (PK) study. Shares of the specialty pharmaceutical company fell 6.98% to end Monday’s trading session at $3.20 a share.

Evoke Pharma Inc. (NASDAQ:EVOK)

New Drug Application

The sell-off added fuel to a downtrend that has plagued the stock in recent trading sessions. Evoke Pharma Inc. (NASDAQ:EVOK) has struggled to close above the $4 a share mark on two attempts amidst concerns that an uptrend, which began in August, could be losing momentum. However, the stock has outperformed the overall industry and is up by more than 40% for the year.

The stock is currently rated as a “Strong Buy” by one analyst firm, a “Hold” by three firms, and a “Sell” by one firm, according to data compiled by Zack Investment research

The topline clinical results come from a trial that sought to demonstrate that the company’s proposed novel treatment for diabetic gastroparesis has similar systemic exposure to Reglan Tablets. Buoyed by the positive results, the company intends to submit a New Drug Application (NDA) with a selected dose of Gimoti to the U.S. Food and Drug Administration (FDA). Gimoti is Evoke Pharma Inc. (NASDAQ:EVOK) lead candidate drug for the treatment of symptoms associated with acute and recurrent diabetic gastroparesis. Last month, the company completed subject dosing as part of an ongoing pharmacokinetic study. Results are expected in the fourth quarter.

The company is preparing the NDA application in partnership with RHO, a well-established research organization that that has worked on other successful gastrointestinal NDA submissions

“In the first quarter of 2018, we will submit the NDA with these PK data, as well as safety and efficacy data from five prior Evoke clinical studies in healthy volunteers and patients with diabetic gastroparesis. We believe Gimoti has the potential to become the new standard of care for patients suffering from this debilitating disease,” said CEO David Gonyer.

Q2 Financial Results

Separately, Evoke Pharmaceuticals reported a net loss of (-$1.6) million for the second quarter, nearly half a net loss of (-$3) million reported last year. Net loss in the quarter was partially offset by $1.3 million associated with a change in the fair value of warrant liability.

Research and development expenses in the quarter came in at $2 million compared to $2.1 million reported in Q2, 2016. Evoke Pharma Inc. (NASDAQ:EVOK) had approximately $12.6 million in cash and cash equivalent as of June 30, 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EVOK and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) Rockets on Open!

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) shares are rocketing on the back of a press release by the biotechnology company that it is making compounded Cyclosporine-based formulations available for physicians to consider prescribing as customizable, and possibly lower-cost alternative, to Restasis® for sufferers of dry-eye disease. Within 30 minutes IMMY shares jumped over 80% on a volume figure that is over 230 times its daily average.

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) is an ophthalmology-focused pharmaceutical company that produces and dispenses high quality innovative medications in all 50 states. The CEO of Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), Mark L. Baum, stated “While there are an estimated 30 million Americans suffering from Dry Eye Disease, only a small fraction of these patients receive therapy. Topical Cyclosporine, which is an off-patent and inexpensive drug, can cost more than $5,000 per year when it is purchased in the commercially available form of Restasis®.”

IMMY Stock Performance

Sales posted by Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) have increased each year since 2014 when it reported a figure of $1.7 million. Bu 2016 sales had improved to $19.9 million. Unfortunately, that uptrend in sales has not been duplicated in earnings. IMMY shareholders have been experiencing losses for the past five years. In 2015, IMMY stock lost (-$1.66) per share. For 2016, the company posted a per share loss of (-$1.50). Also troubling Imprimis investors is the continuing, value-destroying share dilution. In 2012, 4.49 million shares were outstanding. That number grew to 12.74 by 2016.

While IMMY stock is on fire today, the shares have not been doing well. Prior to today, IMMY shares lost over 50% and are down over 66% over the past six months. But the company does not appear to be in financial peril. According to recent reports the biotechnology company has a cash per share figure of $0.21. Analysts rate the shares a “Strong Buy” and assign it a $5.00 price target.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMMY and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.